CM
TLSI icon

Crestline Management’s TriSalus Life Sciences TLSI Stock Holding History

Crestline Management’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-61,950
Closed -$610K – 262
2022
Q2 		$610K Hold
61,950
– – 0.08% 153
2022
Q1 		$607K Buy
61,950
+8,100
+15% +$79.9K 0.07% 161
2021
Q4 		$532K Hold
53,850
– – 0.04% 158
2021
Q3 		$535K Buy
+53,850
New +$527K 0.05% 149

Other funds holding TLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Crestline Management's TLSI Position: Q3 2022 in Review

Crestline Management sold out of TriSalus Life Sciences (TLSI) in Q3 2022, closing a stake of 61,950 shares — an estimated $610K sold.

Crestline Management first reported a position in TLSI in Q3 2021 and held it in 4 quarters. The position peaked at $610K in Q2 2022. 72 funds tracked by Wall St. Rank hold TLSI as of Q3 2022.

  • Crestline Management reported no remaining TriSalus Life Sciences position as of Q3 2022 after selling out during the quarter.
  • Crestline Management sold 61,950 TriSalus Life Sciences shares in Q3 2022, an estimated $610K.
  • Crestline Management first reported a position in TriSalus Life Sciences in Q3 2021 and held it in 4 quarters.
  • Crestline Management's TriSalus Life Sciences position peaked at $610K in Q2 2022.
  • 72 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2022.

Based on Crestline Management's 13F filing for Q3 2022, filed 14 Nov 2022.